We will evaluate the performance of artificial intelligence tools for breast cancer treatment by looking at multiple dimensions, including accuracy, robustness, fairness, usability, confidence and productivity.
Our goal is to build and validate AI tools that overcome common challenges in medicine, such as population-based biases, uncertainty, explanability, usability and data harmonisation.
The ultimate goal of RadioVal is to provide validated artificial intelligence tools that clinicians understand, trust and use in clinical practice so they more effectively treat breast cancer patients.
Explore our news archive for past articles, updates, and insights on the topics that matter to you
At this year’s International Pharmaceutical Federation (FIP) World Congress in Copenhagen, Carina Dantas, CEO of SHINE 2Europe, spotlighted the transformative
We are delighted to announce that RadioVal will be represented at the upcoming MICCAI 2025 main conference, the leading international
The RadioVal consortium brings together 16 partners from 13 countries.
You can find out more about the consortium partners, the individual expertise and the involved staff on the consortium overview page.
Find out more about our Work Plan and how we are working to introduce radiomic artificial intelligence for the prediction of neoadjuvant chemotherapy treatment efficacy.
Receive our latest blog posts directly in your inbox!